Table 2.
Results
| Standard of practice | Nirsevimab | Change (%) | |
|---|---|---|---|
| Health events | |||
| Inpatient hospitalizations (incl. PICU and MV) | 17,179*–19,607 | 7330*–8128 | 9849 (57)*–11,479 (59) |
| PICU (incl. MV) | 2932*–3675 | 1251*–1523 | 1681 (57)*–2151 (59) |
| MV | 172*–525 | 73*–217 | 98 (57)*–307 (59) |
| ER visits | 57,654–191,115* | 27,100–88,748* | 30,554 (53)–102,367 (54)* |
| PC visits | 219,083–219,970* | 102,147*–102,719 | 116,364 (53)–117,823 (54)* |
| RSV-related mortality | 14*–14 | 7*–7 | 8 (53)*–8 (53) |
| Recurrent wheezing | 12,884*–14,705 | 5498*–6096 | 7386 (57)*–8609 (59) |
| Costs | |||
| Inpatient hospitalizations | SAR 94,726,973*–105,929,818 | SAR 40,420,233*–43,912,600 | SAR 54,306,740 (57)*–62,017,217 (59) |
| PICU | SAR 174,070,120*–198,670,409 | SAR 74,276,150*–82,357,682 | SAR 99,793,970 (57)*–116,312,726 (59) |
| MV | SAR 11,662,796*–35,614,793 | SAR 4,976,544*–14,763,909 | SAR 6,686,252 (57)*–20,850,884 (59) |
| ER visits | SAR 86,480,896–286,672,815* | SAR 40,650,224–133,122,187* | SAR 45,830,672 (53)–153,550,628 (54)* |
| PC visits | SAR 39,434,984–39,594,586* | SAR 18,386,470*–18,489,444 | SAR 20,945,540 (53)–21,208,116 (54)* |
| Recurrent wheezing | SAR 12,455,582*–14,215,854 | SAR 5,314,827*–5,893,101 | SAR 7,140,754 (57)*–8,322,753 (59) |
| Total hospitalization cost (incl. PICU and MV) | SAR 280,459,889*–340,215,019 | SAR 119,672,927*–141,034,192 | SAR 160,786,962 (57)*–199,180,828 (59) |
| Total MA-LRTD cost (hospitalization, ER and PC visits) | SAR 466,130,899–606,727,290* | SAR 200,173,860–271,181,584* | SAR 265,957,040 (57)–335,545,706 (55)* |
| Total healthcare cost | SAR 480,346,754–619,182,871* | SAR 206,066,961–276,496,411* | SAR 274,279,793 (57)–342,686,460 (55)* |
ER emergency room, MA-LRTD medically attended lower respiratory tract disease, MV mechanical ventilation, PC primary care, PICU pediatric intensive care unit, SoP standard of practice
*Denotes results estimated using inputs based on local expert opinion